Identification of Causal T-Cell Mechanisms in Immune Checkpoint Inhibitor Induced Myocarditis
免疫检查点抑制剂诱发心肌炎的 T 细胞机制鉴定
基本信息
- 批准号:10712007
- 负责人:
- 金额:$ 4.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-15 至 2026-12-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAdvanced Malignant NeoplasmAffectAntibody Binding SitesAntigensArrhythmiaAutoantigensAutoimmune DiseasesCCR5 geneCD8-Positive T-LymphocytesCancer PatientCardiacCardiac DeathCardiovascular systemCellsCessation of lifeClonal ExpansionComputational algorithmCytotoxic T-LymphocytesDataDiseaseDrug Side EffectsEnsureGroupingHeartHeart failureHistopathologyImmuneImmune checkpoint inhibitorImmunological ModelsInflammationInflammatoryKnockout MiceKnowledgeLifeLymphocyteLymphocytic InfiltrateMalignant NeoplasmsMediatingMolecularMonoclonal AntibodiesMusMyocardialMyocarditisPathogenesisPathogenicityPathologicPatientsPhysiciansPlayPopulationPreventionRANTESReactionReportingRoleSafetyScientistSignal TransductionT cell receptor repertoire sequencingT cell therapyT-Cell ActivationT-LymphocyteT-Lymphocyte SubsetsTestingTherapeuticTissuesToxic effectUp-RegulationWorkage groupcandidate identificationcheckpoint therapychemokinecytotoxiccytotoxicityexperimental studyin vivoinsightknock-downmyocardial damagemyocardial injuryneoplastic cellnovelprogrammed cell death ligand 1programmed cell death protein 1receptorside effectsingle-cell RNA sequencingsudden cardiac death
项目摘要
PROJECT SUMMARY/ABSTRACT
Myocarditis, pathologic inflammation of the heart, is a serious cause of sudden cardiac death affecting
patients of all age groups. Immune checkpoint inhibitors (ICIs) are monoclonal antibodies to cytotoxic T-cell
antigen-4 (CTLA-4) or programmed death-1 (PD-1)/programmed death-1 ligand (PD-1L) used as novel cancer
therapeutics to release intrinsic brakes on T-cell cytotoxicity against tumor cells. Although ICIs are now relied
upon to treat many advanced cancers, fulminant myocarditis has been reported as a life-threatening side effect
of these drugs, leading to severe arrhythmias, heart failure and death. Under histopathology, an acute
lymphocytic infiltrate is found in the heart, and multiple lines of evidence point to a T-cell and antigen-mediated
phenomenon. In this proposal, Dr. Zhu’s preliminary data in ICI myocarditis patients and a germline PD-1
knockout mouse model of ICI myocarditis (MRL-Pdcd1-/-) demonstrates a population of clonally-expanded
cytotoxic effector CD8+ T-cells thought to play a critical role in this disease, with upregulation of the chemokine
RANTES (CCL5) and its receptor (CCR5). Dr. Zhu hypothesizes that ICI myocarditis is caused by the clonal
expansion of cytotoxic effector CD8+ T-cells in the heart, whose pathogenesis is potentiated by signaling from
CCL5, and she will aim to test this hypothesis using single-cell RNA-seq/single-cell TCR sequencing and T-cell
adoptive transfer experiments (Aim 1), as well as and ex-vivo/in-vivo knockdown of CCR5 in MRL-Pdcd1-/- mice
(Aim 2).
Although T-cell clonal analysis of patient heart tissues suggest the existence of a cardiac-specific antigen
in ICI-induced myocarditis, the identity of such antigen(s) remains elusive. Understanding the culprit antigens in
this disease may lead to novel insights in T-cell mediated myocardial damage. In the second part of her proposal,
Dr. Zhu hypothesizes that ICI-induced myocarditis is an autoimmune disorder caused by cardiac-specific auto-
antigens that trigger the activation/clonal expansion of T-cells, leading to myocardial inflammation. In Aim 3,
she will utilize the novel computational algorithm called GLIPH (Grouping Lymphocyte Interactions by Paratope
Hotspots) to identify candidate pathogenic antigens in ICI myocarditis. Dr. Zhu’s work will bridge a major
knowledge gap in the field of cardiac inflammation and identify culprit T-cell subsets and disease-causing
antigens in ICI myocarditis and T-cell induced myocardial injury. The completion of this proposal will provide a
platform for Dr. Zhu’s successful transition to an independent physician scientist investigating immune
mechanisms in cardiac inflammation/toxicity.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Han Zhu其他文献
Han Zhu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Han Zhu', 18)}}的其他基金
Identification of Causal T-Cell Mechanisms in Immune Checkpoint Inhibitor Induced Myocarditis
免疫检查点抑制剂诱发心肌炎的 T 细胞机制鉴定
- 批准号:
10351289 - 财政年份:2022
- 资助金额:
$ 4.84万 - 项目类别:
Identification of Causal T-Cell Mechanisms in Immune Checkpoint Inhibitor Induced Myocarditis
免疫检查点抑制剂诱发心肌炎的 T 细胞机制鉴定
- 批准号:
10545278 - 财政年份:2022
- 资助金额:
$ 4.84万 - 项目类别:
Identification of Causal Antigens in Immune Checkpoint Inhibitor-Induced Myocarditis
免疫检查点抑制剂诱发的心肌炎的致病抗原的鉴定
- 批准号:
10022140 - 财政年份:2019
- 资助金额:
$ 4.84万 - 项目类别: